Capital Markets Day: Commercial Execution and Innovation in Obesity Care
22
Commercial execution and innovation
Obesity care
The interim analysis for the SELECT trial is expected to be
conducted in the third quarter of 2022
SELECT trial with 17,500 people with obesity
Background of interim analysis
Novo NordiskⓇ
Semaglutide 2.4 mg
R
1:1
Placebo
Objective
Event driven
5 weeks
follow-up
Demonstrate that semaglutide 2.4 mg lowers the incidence of MACE
vs placebo
Primary endpoint
Time from randomisation to first occurrence of MACE¹
Secondary endpoints
CV death, all-cause death, 5-point MACE composite, composite HF,
composite nephropathy, glucose metabolism, other metabolic
parameters
1 MACE includes: Non-fatal myocardial infarction, non-fatal stroke, cardiovascular death
MACE: Major adverse cardiovascular events; HF: Heart failure; CV: Cardiovascular
.
Number of MACE events for interim analysis expected to be accumulated
in the third quarter of 2022
Interim analysis will be conducted by the Data Monitoring Committee
A decision to stop the trial based on interim analysis follows assessment
of the totality of data
If the trial is stopped due to efficacy, SELECT is expected to complete
around turn of the year
If continued, SELECT is expected to complete in 2023 when all pre-
specified number of MACE events are accrued
SELECT-LIFE: After the finalisation of SELECT, a non-interventional study
to evaluate long-term post trial effects will be initiated
CMD22
CAPITAL MARKETS DAYView entire presentation